Arbutus Biopharma (ABUS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on the stock ...

We recently published a list of 10 Best Nasdaq Stocks Under $5 to Buy. In this article, we are going to take a look at where Arbutus Biopharma Corp.

David C. Hastings, the Chief Financial Officer of Arbutus Biopharma Corp (NASDAQ:ABUS), recently sold 22,183 common shares of the company. The shares were sold at an average price of $3.283 ...

Arbutus Biopharma stock opened at $3.21 on Tuesday. The business has a fifty day moving average price of $3.41 and a 200-day moving average price of $3.72. The stock has a market capitalization of ...

China Universal Asset Management Co. Ltd. grew its stake in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 10.7% in the fourth quarter, according to the company in its most recent Form 13F ...

In this article, we are going to take a look at where Arbutus Biopharma Corporation (NASDAQ:ABUS) stands against the other stocks featured in Jim Cramer’s Lightning Round. Jim Cramer ...

David C. Hastings, the Chief Financial Officer of Arbutus Biopharma Corp (NASDAQ:ABUS), recently sold 22,183 common shares of ...

In this article, we are going to take a look at where Arbutus Biopharma Corporation (NASDAQ:ABUS) stands against the other stocks featured in Jim Cramer’s Lightning Round. Jim Cramer, the host of Mad ...

WARMINSTER, PA — Arbutus Biopharma Corporation (NASDAQ: ABUS) has unveiled its strategic objectives for 2025 alongside an encouraging financial update, emphasizing progress in its efforts to ...

DUBLIN, Feb. 5, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the Oppenheimer 35 th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 12:00 ...